Join the club for FREE to access the whole archive and other member benefits.

LEAF interviews Lewis Gruber about targeting cancer and senescent cells


Key points from article :

Lewis Gruber is CEO and Co-Founder of SIWA Therapeutics .

SIWA has found a marker that’s on cancer cells and senescent cells.

Manufacture a monoclonal antibody in Chinese Hamster Ovary (CHO) cells.

Senotherapeutic is tailored for a specific biomarker present in all humans.

SIWA 318H binds to proteins on the surface of oxidatively damaged cells.

Warburg marker is a side product of glycolysis.

Removes dysfunctional cells and promote their replacement.

Cancerous senescent cells may resort to glycolysis to get additional ATP.

Every type of cancer we’ve tested has bound to our antibody.

Would be hard for cancer cell to evolve around such a basic biological process.

Done preliminary studies in mice, and have a candidate vaccine.

Using humanized mice, and working toward a clinical trial.

Removing a senescent cells can interfere with wound healing or fetal development.

Biomarker caused by glycolysis seen in all types of cancer - exciting possibilities

Mentioned in this article:

Click on resource name for more details.

Lewis Gruber

CEO, CSO and Co-Founder of SIWA Therapeutics

SIWA Therapeutics

Biotechnology company producing therapy that targets and destroys senescent cells.